Department of Family Medicine and Primary Care, University of Hong Kong, Ap Lei Chau, Hong Kong.
Ann Surg Oncol. 2014 Mar;21(3):767-77. doi: 10.1245/s10434-013-3398-3. Epub 2013 Nov 26.
Although prophylactic central neck dissection (pCND) may reduce future locoregional recurrence after total thyroidectomy (TT) for low-risk papillary thyroid carcinoma (PTC), it is associated with a higher initial morbidity. We aimed to compare the long-term cost-effectiveness between TT with pCND (TT+pCND) and TT alone in the institution's perspective.
Our case definition was a hypothetical cohort of 100,000 nonpregnant female patients aged 50 years with a 1.5-cm cN0 PTC within one lobe. A Markov decision tree model was constructed to compare the estimated cost-effectiveness between TT+pCND and TT alone after a 20-year period. Outcome probabilities, utilities, and costs were estimated from the literature. The threshold for cost-effectiveness was set at US$50,000 per quality-adjusted life year (QALY). Sensitivity and threshold analyses were used to examine model uncertainty.
Each patient who underwent TT+pCND instead of TT alone cost an extra US$34.52 but gained an additional 0.323 QALY. In fact, in the sensitivity analysis, TT+pCND became cost-effective 9 years after the initial operation. In the threshold analysis, none of the scenarios that could change this conclusion appeared clinically possible or likely. However, TT+pCND became cost-saving (i.e., less costly and more cost-effective) at 20 years if associated permanent vocal cord palsy was kept ≤ 1.37 %, permanent hypoparathyroidism was ≤ 1.20 %, and/or postoperative radioiodine ablation use was ≤ 73.64 %.
In the institution's perspective, routine pCND for low-risk PTC began to become cost-effective 9 years after initial surgery and became cost-saving at 20 years if postoperative radioiodine use and/or permanent surgical complications were kept to a minimum.
尽管预防性中央颈部清扫术(pCND)可能会降低甲状腺全切术(TT)治疗低危甲状腺乳头状癌(PTC)后的局部区域复发率,但它与更高的初始发病率相关。我们旨在从机构角度比较 TT 联合 pCND(TT+pCND)与 TT 单独治疗的长期成本效益。
我们的病例定义是一个假设的队列,包括 100,000 名年龄在 50 岁、有一侧 1.5 厘米 cN0 PTC 的非妊娠女性患者。使用 Markov 决策树模型比较 20 年后 TT+pCND 与 TT 单独治疗的估计成本效益。结局概率、效用和成本均从文献中估计。成本效益的阈值设定为每质量调整生命年(QALY)50,000 美元。使用敏感性和阈值分析来检查模型不确定性。
与 TT 单独治疗相比,每位接受 TT+pCND 治疗的患者额外花费 34.52 美元,但获得了额外的 0.323 QALY。实际上,在敏感性分析中,TT+pCND 在初始手术后 9 年变得具有成本效益。在阈值分析中,没有任何可能改变这一结论的情况在临床上是可行或可能的。然而,如果永久性声带麻痹≤1.37%、永久性甲状旁腺功能减退症≤1.20%和/或术后放射性碘消融使用≤73.64%,则 TT+pCND 在 20 年后可节省成本(即花费更少且更具成本效益)。
从机构角度来看,低危 PTC 的常规 pCND 在初始手术后 9 年开始具有成本效益,并且在 20 年后,如果术后放射性碘的使用和/或永久性手术并发症保持在最低限度,那么就可以节省成本。